Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.83 |
| ▸ | RXRB | P28702 | 8/20 | 0.83 |
| ▸ | RXRG | P48443 | 8/20 | 0.83 |
| ▸ | RARB | P10826 | 5/20 | 0.83 |
| ▸ | RARG | P13631 | 5/20 | 0.83 |
| ▸ | RARA | P10276 | 4/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181011 | 0.94 | RXRA (0.88) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL30054740 | 0.91 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL726140 | 0.91 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL5540253 | 0.89 | RXRA (0.80) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6906197 | 0.88 | RXRA (0.79) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL4910483 | 0.86 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL4009257 | 0.86 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL2591205 | 0.85 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL12181009 | 0.85 | RXRA (0.79) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6901726 | 0.85 | RXRA (0.69) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | BALKAN BORK (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2427209-A1 | ANTI-IL1- ANTIBODY COMBINATION THERAPY | Novartis AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128092-A1 | ANTI-IL1-β ANTIBODY COMBINATION THERAPY | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-1296974-B1 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080076811-A1 | COMBINATIONS COMPRISING DEPEPTIDYPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | BALKAN BORK | 2008-03-27 | — | — | US | disclosed |
| EP-1743655-A1 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| EP-1741445-A2 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| EP-1741447-A2 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| EP-1741446-A2 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2003080070-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITTOR AND AN INSULIN SECRETOR ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003076393-A1 | SALTS OF NATEGLINIDE | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |
| US-20030114469-A1 | Combinations | COHEN DAVID SAUL (US) | 2003-06-19 | — | — | US | disclosed |
| WO-2003028730-A2 | PHARMACEUTICAL COMBINATIONS OF PDE-V INHIBITORS AND OTHER AGENTS | NOVARTIS AG (CH) | 2003-04-10 | — | — | WO | disclosed |
| EP-1296974-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | disclosed |
| EP-1248604-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | Novartis AG (CH) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002072146-A2 | COMBINATION OF NATEGLINIDE OR REPAGLINIDE WITH AT LEAST ONE FURTHER ANTIDIABETIC COMPOUND | NOVARTIS AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| WO-2001096295-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001052825-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114469-A1 | Combinations | GPR119, SLC5A1, HMGCR | RXRA 1689/4885RXRB 1586/4885RXRG 1233/4885 |
| US-20080076811-A1 | COMBINATIONS COMPRISING DEPEPTIDYPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | G6PC1, GCK, PDK4 | RXRA 1914/4885RXRB 1900/4885RXRG 1413/4885 |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | DPP4, DPP7, DPP3 | RXRA 2323/4885RXRB 2413/4885RXRG 2114/4885 |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | RXRA 3641/4885RXRB 3595/4885RXRG 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.